Advertisement
Advertisement
EYPT
EyePoint, Inc. Common Stock
13.89
USDSponsored
+1.06
+8.26%
Aug 07, 15:59 UTC -4
Closed
After-Market
13.90
+0.01
+0.07%
EYPT Earnings Reports
Positive Surprise Ratio
EYPT beat 14 of 31 last estimates.
45%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$319.85K
/-$0.85
Implied change from Q2 26 (Revenue/ EPS)
-37.28%
/-22.02%
Implied change from Q3 25 (Revenue/ EPS)
-66.89%
/--
EyePoint, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, EYPT reported earnings of -1.09 USD per share (EPS) for Q2 26, missing the estimate of -0.97 USD, resulting in a -12.31% surprise. Revenue reached 510.00 thousand, compared to an expected 415.00 thousand, with a 22.89% difference. The market reacted with a +4.97% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.85 USD, with revenue projected to reach 319.85 thousand USD, implying an decrease of -22.02% EPS, and decrease of -37.28% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were EyePoint, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, EyePoint, Inc. Common Stock reported EPS of -$1.09, missing estimates by -12.31%, and revenue of $510.00K, 22.89% above expectations.
How did the market react to EyePoint, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 4.97%, changed from $11.67 before the earnings release to $12.25 the day after.
When is EyePoint, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for EyePoint, Inc. Common Stock's next earnings report?
Based on 7
analysts, EyePoint, Inc. Common Stock is expected to report EPS of -$0.85 and revenue of $319.85K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement